journal
https://read.qxmd.com/read/38601838/three-once-weekly-intra-articular-injections-of-hylan-g-f-20-significantly-improve-pain-relief-compared-with-placebo-in-patients-with-chronic-idiopathic-knee-osteoarthritis-a-single-centre-evaluator-blinded-and-patient-blinded-randomized-controlled-trial
#1
JOURNAL ARTICLE
Michael Langworthy, Peter Lascarides, Wilson Ngai, Kevin Steele, Yili Huang
BACKGROUND: Clinical trials on the use of viscosupplementation with hyaluronic acid (HA) in patients with knee osteoarthritis (KOA) are inconsistent, making it challenging to determine its value in clinical practice. One issue is the availability of various HA products on the market; differences in their chemical features can impact patient outcomes. Herein, we assess the efficacy and safety of three once-weekly intra-articular (IA) injections of Hylan G-F 20, a high-molecular-weight and highly crosslinked HA product, in patients with KOA...
2024: Drugs in Context
https://read.qxmd.com/read/38601837/corrigendum-vulnerable-period-in-heart-failure-a-window-of-opportunity-for-the-optimization-of-treatment-a-statement-by-mexican-experts
#2
(no author information available yet)
[This corrects the article DOI: 10.7573/dic.2023-8-1.].
2024: Drugs in Context
https://read.qxmd.com/read/38510314/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-a-52-week-real-world-portuguese-multicentric-study
#3
JOURNAL ARTICLE
Tiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, Paulo Ferreira
BACKGROUND: Real-world evidence plays a pivotal role in validating the efficacy of biologic drugs beyond the controlled environment of randomized trials. This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal. METHODS: This multicentric, prospective, observational study included adult patients with moderate-to-severe psoriasis. All participants received tildrakizumab 100 mg at weeks 0 and 4, followed by a maintenance dose every 12 weeks, and were monitored for 52 weeks...
2024: Drugs in Context
https://read.qxmd.com/read/38510313/real-practice-management-and-treatment-of-idiopathic-multicentric-castleman-disease-with-siltuximab-a-collection-of-clinical-experiences
#4
JOURNAL ARTICLE
Bernardo Rossini, Nicola Cecchi, Felice Clemente, Maria Rosaria De Paolis, Stefan Hohaus, Vanessa Innao, Mariano Lucignano, Roberto Massaiu, Giovanna Palumbo, Gian Matteo Rigolin, Francesca Gaia Rossi, Luisa Verga, Attilio Guarini
Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for idiopathic multicentric CD and is recommended as first-line therapy in treatment guidelines. Despite the extensive characterization of siltuximab treatment in clinical trials, available evidence from real-world practice is still scant...
2024: Drugs in Context
https://read.qxmd.com/read/38510312/prevention-of-post-contrast-kidney-injury-in-patients-with-cancer
#5
REVIEW
Emanuele Grassedonio, Lorena Incorvaia, Marco Guarneri, Fabio Guagnini, Massimo Midiri
Post-contrast acute kidney injury is defined as a nephropathy with an increase in serum creatinine of >0.3 mg/dL (or >26.5 μmol/L) or >1.5-times the baseline within 48-72 h of intravascular administration of a contrast medium. Patients with cancer have an increased risk of post-contrast acute kidney injury not only related to the frequent use of contrast medium for computed tomography scans but also to other factors, including the type of tumour, age, oncological therapies, use of other nephrotoxic agents and dehydration...
2024: Drugs in Context
https://read.qxmd.com/read/38440072/autoimmune-findings-in-patients-with-silicosis-in-spain
#6
JOURNAL ARTICLE
Coral González Fernández, Jose Antonio Ros Lucas, Maria Molina Molina, Juan Rigual Bobillo, Rogelio Alejandro García Montenegro, Raquel Fernández González, Ana Jaureguiza Oriol, Jose Abal Arca
BACKGROUND: Occupational exposure to silica is related to autoimmune diseases and features of autoimmunity, mainly autoantibodies. The study objectives were to estimate the prevalence of silicosis with associated autoimmune findings or diagnosed autoimmune diseases in Spain, and to assess the clinical and functional characteristics of affected patients. METHODS: This is a multicentre prospective study in patients diagnosed with silicosis. Autoantibodies analysed were antinuclear antibodies, isotypes IgA, IgM and IgG, rheumatoid factor, anticyclic citrullinated peptide, anti-Scl70, anti-Ro, and anti-LA...
2024: Drugs in Context
https://read.qxmd.com/read/38384931/effect-of-nabiximols-oromucosal-spray-sativex-%C3%A2-on-symptoms-associated-with-multiple-sclerosis-related-spasticity-a-case-series
#7
JOURNAL ARTICLE
Niklas Garde, Markus Heibel
Spasticity and its related symptoms of spasms, pain, sleep disturbance and bladder dysfunction are common in persons with multiple sclerosis (MS) and may be interconnected through a common pathophysiology and/or may trigger and worsen each other. Tetrahydrocannabinol-cannabidiol (nabiximols) oromucosal spray (Sativex) is an add-on treatment for adults with moderate-to-severe MS spasticity who fail to respond adequately to conventional oral medications. There is evidence that nabiximols can ameliorate spasticity-associated symptoms irrespective of its effect on spasticity...
2024: Drugs in Context
https://read.qxmd.com/read/38384930/medicines-policy-access-and-use-in-mexico-a-systematic-literature-review-2000-2022
#8
REVIEW
Laura Cristina Vargas López, David Chávez Gallegos, Dolly Marlene Blanco Borjas, Veronika J Wirtz
BACKGROUND: Research on medicines access and use is heterogeneous and can be challenging for decision-makers to interpret. Pharmaceutical policy is an additional component for study and is the foundation for the promotion of access and use of medicines. This systematic review summarizes findings from the literature on medicines policy, access and use over the past two decades in Mexico and identifies research gaps that should be addressed. METHODS: A systematic review of the literature published between 2000 and 2022 was conducted to identify publications on medicines policy, access and use in Mexico...
2024: Drugs in Context
https://read.qxmd.com/read/38332945/efficacy-and-activity-of-treatments-after-progression-from-palbociclib-plus-endocrine-therapy-in-patients-with-hr-her2-metastatic-breast-cancer-a-prospective-monocentric-study
#9
JOURNAL ARTICLE
Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti
BACKGROUND: Breast cancer is the most frequent tumour worldwide, and the HR+ /HER2- subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represents the gold standard for first-line or second-line therapies. However, the optimal therapeutic strategy after CDK4/6i progression is still a matter of debate, with several randomized clinical trials still ongoing. PATIENTS AND METHODS: This is an observational, prospective, real-world study including women with HR+ /HER2- metastatic breast cancer progressing to palbociclib plus ET...
2024: Drugs in Context
https://read.qxmd.com/read/38332944/chronic-liver-disease-and-management-with-silymarin-an-introductory-review-of-a-clinical-case-collection
#10
REVIEW
Francesco Angelico
Chronic liver disease (CLD) is a significant global health concern and generally leads to fibrosis, cirrhosis and hepatocellular carcinoma. Various factors, such as metabolic abnormalities, viral infections, alcoholism, genetics and autoimmune responses, contribute to liver damage. CLD is characterized by different phenotypes, including non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, drug-induced liver injury and alcoholic liver disease. These conditions have seen an increase in comorbidities and hospitalizations over the past decade, imposing a substantial burden on patients and healthcare systems...
2024: Drugs in Context
https://read.qxmd.com/read/38264405/the-magnitude-and-predictors-of-self-medication-amongst-street-dwellers-in-ethiopia-a-multicentre-study
#11
JOURNAL ARTICLE
Tirsit Ketsela Zeleke, Bekalu Dessie Alamirew, Zegaye Agmassie Bazezew, Muluken Adela Alemu, Abdisa Gemedi Jara, Rahel Belete Abebe
BACKGROUND: Low levels of living standards amongst street dwellers worldwide limit their access to conventional healthcare services, resulting in self-medication use for the treatment of an illness. Nevertheless, self-medication use has risks, including adverse drug reactions, increased polypharmacy, drug resistance, drug dependence, drug interactions and incorrect diagnosis. Ethiopia has a large street-dwelling community; however, there are no studies conducted in Ethiopia assessing self-medication use amongst street dwellers...
2024: Drugs in Context
https://read.qxmd.com/read/38264404/how-to-handle-off-label-prescriptions-of-rupatadine-a-second-generation-antihistamine-and-paf-antagonist-a-review
#12
REVIEW
Iñaki Izquierdo, Laia Casas, Susana Cabrera, Alberto Fernandez
The off-label use of second-generation antihistamines, used outside of the formal indications authorized by regulatory authorities, in different age groups, doses or in special populations, is very common for many allergic, autoimmune and dermatological diseases. The off-label use of rupatadine (a second-generation antihistamine with PAF antagonist activity) in these conditions is reviewed here, including in combination with immunotherapy in the treatment of food allergy or allergic rhinitis, at high doses in chronic urticaria, and with prescriptions of less common but challenging conditions such as skin pruritus or mast cell activation disorders like mastocytosis...
2024: Drugs in Context
https://read.qxmd.com/read/38264403/review-and-expert-opinion-on-mafld-oxidative-stress-and-multifunctional-management
#13
REVIEW
Francesco Angelico, Diana Alcantara-Payawal, Rafiz Abdul Rani, Norlaila Mustafa, Nuntakorn Thongtang, Roongruedee Chaiteerakij, Chalermrat Bunchorntavakul, Apichard Sukonthasarn
Metabolic-associated fatty-liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most widespread and emerging chronic liver disease worldwide, with increasing prevalence rates also in the Asia-Pacific region. The disease has a high socio-economic burden as it negatively impacts the finances and quality of life of individuals affected and has a major burden on healthcare systems. The most important pathological event in MAFLD aetiopathogenesis is oxidative stress, which leads to functional and structural abnormalities in the liver as well as being involved in the development of other concomitant cardiometabolic diseases...
2024: Drugs in Context
https://read.qxmd.com/read/38264402/vulnerable-period-in-heart-failure-a-window-of-opportunity-for-the-optimization-of-treatment-a-statement-by-mexican-experts
#14
REVIEW
José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, Juan Betuel Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar
Acute heart failure (HF) is associated with poor prognosis. After the acute event, there is a vulnerable period during which the patient has a marked risk of readmission or death. Therefore, early optimization of treatment is mandatory during the vulnerable period. The objective of this article is to provide recommendations to address the management of patients with HF during the vulnerable period from a practical point of view. A group of Mexican experts met to prepare a consensus document. The vulnerable period, with a duration of up to 6 months after the acute event - either hospitalization, visit to the emergency department or the outpatient clinic/day hospital - represents a real window of opportunity to improve outcomes for these patients...
2024: Drugs in Context
https://read.qxmd.com/read/38264401/high-dose-amphotericin-yay-or-nay-a-case-series-and-literature-review
#15
REVIEW
Kayla R Stover, Taylor E Jordan, Jamie L Wagner, Katie E Barber
Invasive fungal infections pose significant morbidity and mortality risks, particularly those caused by moulds. Available antifungal classes are limited by toxicities and are increasingly susceptible to resistance, particularly amongst challenging fungal pathogens. The purpose of this case series and literature review was to characterize the use of a high-dose lipid formulation of amphotericin B. A case series is presented including patients who received high-dose lipid formulation amphotericin B (≥7...
2024: Drugs in Context
https://read.qxmd.com/read/38188263/diuretic-resistance-and-the-role-of-albumin-in-congestive-heart-failure
#16
REVIEW
Carol Fernandez Hazim, Gustavo Duarte, Ana P Urena, Swati Jain, Rishabh Mishra, Timothy J Vittorio, Miguel Rodriguez-Guerra
Diuresis with loop diuretics is the mainstay treatment for volume optimization in patients with congestive heart failure, in which perfusion and volume expansion play a crucial role. There are robust guidelines with extensive evidence for the management of heart failure; however, clear guidance is needed for patients who do not respond to standard diuretic treatment. Diuretic resistance (DR) can be defined as an insufficient quantity of natriuresis with proper diuretic therapy. A combination of diuretic regimens is used to overcome DR and, more recently, SGLT2 inhibitors have been shown to improve diuresis...
2023: Drugs in Context
https://read.qxmd.com/read/38148831/corrigendum-precautions-in-the-management-of-opioid-agonist-therapy-from-target-population-characteristics-to-new-formulations-and-post-marketing-monitoring-a-focus-on-the-italian-system
#17
https://read.qxmd.com/read/38148830/fentanyl-in-cancer-pain-management-avoiding-hasty-judgments-and-discerning-its-potential-benefits
#18
REVIEW
Arturo Cuomo
Cancer pain is an important challenge in treatment and requires a rapid onset of action for its control. In particular, breakthrough cancer pain (BTcP) should be adequately controlled with a stable dose of a short-acting oral opioid. Fentanyl is a synthetic, highly selective opioid with many advantageous chemical properties, including high lipophilicity and distinct pharmacokinetic properties. It is recommended for pain management in a variety of settings, including acute pain, chronic pain and BTcP. To date, its variously designed formulations allow non-invasive administration; amongst others, sublingual fentanyl has proven useful in the management of BTcP and in improving the quality of life of patients with cancer...
2023: Drugs in Context
https://read.qxmd.com/read/38148829/efficacy-and-safety-of-itopride-sr-for-upper-gastrointestinal-symptoms-in-patients-with-diabetic-gastroparesis-real-world-evidence-from-pakistan
#19
JOURNAL ARTICLE
Adil Ramzan, Ghulam Fareed Memon, Asif Ali Shaikh, Mohammad Masood Khoso, Tariq Meher, Adnan Ghafoor, Naveed Ahmed Shehzad, Safian Ahmed, Zunaira Nawaz, Muhammad Rehan, Tariq Saeed, Waqar Taj, Sakhawat Abbass, Ramiz Khan, Hamza Ehsan, Abubakkar Alam, Bilal Manzoor, Muhammad Nawaz Khan, Khalid Mahmood Yahya, Farhan Mukhtiar, Muhammad Asif Javed, Muhammad Usman Sheikh, Danish Janjua, Sumerah Jabeen, Junaid Zafar, Riaz Hussain Khokhar, Madeeha Nazar, Neeta Maheshwary, Muhammad Athar Khan
BACKGROUND: Gastroparesis is a serious condition that can be caused by diabetes, surgery or infection, or can be idiopathic. When there is no mechanical obstruction, gastroparesis is characterized by delayed stomach emptying. Itopride, a prokinetic drug, inhibits acetylcholinesterase activity in addition to antagonizing dopamine D2 receptors. METHODS: This prospective, multicentre study is based on real-world data from 988 patients with a diagnosis of diabetic gastroparesis for index (PAGI-SYM2) evaluation at baseline and week 4 of treatment for upper gastrointestinal disorder symptoms...
2023: Drugs in Context
https://read.qxmd.com/read/38046472/sleep-related-breathing-disorder-central-sleep-apnoea-improved-coincidentally-by-medical-therapy-with-fumarates-dimethyl-fumarate
#20
Abdulmajeed M Albadi, Mana M Alshahrani, Riyad O Allehebi
Central sleep apnoea (CSA) is a sleep disorder characterized by the repeated cessation or reduction of both airflow and ventilatory effort when sleeping. Individuals with central breathing disorders have difficulty in receiving appropriate medical treatment. In this article, we describe a case study of a 31-year-old woman known to have multiple sclerosis and concomitant severe CSA. She received the medication dimethyl fumarate for the treatment of multiple sclerosis, and her CSA significantly improved to mild CSA after the treatment...
2023: Drugs in Context
journal
journal
48111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.